GSK receives FDA accelerated approval for JEMPERLI (dostarlimab-gxly) for adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid tumours
The Pharma Data
AUGUST 17, 2021
Mismatch repair-deficient tumours contain abnormalities that affect the proper repair of DNA when copied in a cell [i]. For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment per institutional guidelines, including hormone replacement as clinically indicated. Initiate hormone replacement as clinically indicated.
Let's personalize your content